{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:34:50Z","timestamp":1793932490512,"version":"4.8.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) is a severe developmental and epileptic encephalopathy characterized by early onset drug-resistant seizures and later cognitive and social impairments. Existing therapies primarily involve antiseizure medications, which have sedative side effects and lack effective treatments for behavioral impairments. Potassium chloride cotransporter (KCC2) activity is regulated by phosphorylation and is a crucial component of the GABAergic inhibitory system. However, KCC2 dysfunction in CDD remains poorly understood. Here, to investigate potential KCC2 dysfunction, we used a constitutive\n                    <jats:italic>Cdkl5<\/jats:italic>\n                    knockout mouse model of CDD. We used liquid chromatography coupled with tandem mass spectrometry and quantitative analysis to examine the unbiased phosphorylation of KCC2. We observed aberrant KCC2 phosphorylation and reduced expression, suggesting reduced KCC2 activity. Examining developmental KCC2 changes revealed significant alterations in key phosphorylation residues and decreased expression between postnatal days 14 and 21. Treatment with the KCC2 activator (OV350) between p10 and p21 saw a significant reduction in infantile spasms compared to vehicle-treated\n                    <jats:italic>Cdkl5<\/jats:italic>\n                    knockout mice. Remarkably, when these mice were adults, the mice that received OV350 as pups had reduced seizure susceptibility and their cognitive and behavioral deficits were alleviated. These findings indicate that enhancing KCC2 function during a critical developmental window may be a promising therapeutic strategy for CDD and other developmental and epileptic encephalopathies.\n                  <\/jats:p>","DOI":"10.1038\/s12276-026-01670-x","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T03:23:49Z","timestamp":1771471429000},"page":"591-604","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["KCC2 activation during postnatal development alleviates long-term deficits in CDKL5-deficient mice"],"prefix":"10.1038","volume":"58","author":[{"given":"Muhammad Nauman","family":"Arshad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Bope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noell","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob S.","family":"Dengler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu Fun Josephine","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua L.","family":"Smalley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiya","family":"Nishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Moss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"1670_CR1","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1093\/brain\/awz195","volume":"142","author":"JD Symonds","year":"2019","unstructured":"Symonds, J. D. et al. Incidence and phenotypes of childhood-onset genetic epilepsies: a prospective population-based national cohort. Brain 142, 2303\u20132318 (2019).","journal-title":"Brain"},{"key":"1670_CR2","first-page":"2095","volume":"248","author":"SR D\u2019Mello","year":"2023","unstructured":"D\u2019Mello, S. R. Rett and Rett-related disorders: common mechanisms for shared symptoms? Exp. Biol. Med. 248, 2095\u20132108 (2023).","journal-title":"Exp. Biol. Med."},{"key":"1670_CR3","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S1474-4422(22)00035-7","volume":"21","author":"H Leonard","year":"2022","unstructured":"Leonard, H. et al. CDKL5 deficiency disorder: clinical features, diagnosis, and management. Lancet Neurol. 21, 563\u2013576 (2022).","journal-title":"Lancet Neurol."},{"key":"1670_CR4","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.yebeh.2014.05.031","volume":"37","author":"KD Laxer","year":"2014","unstructured":"Laxer, K. D. et al. The consequences of refractory epilepsy and its treatment. Epilepsy Behav. 37, 59\u201370 (2014).","journal-title":"Epilepsy Behav."},{"key":"1670_CR5","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S1474-4422(22)00077-1","volume":"21","author":"EMP Knight","year":"2022","unstructured":"Knight, E. M. P. et al. Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 21, 417\u2013427 (2022).","journal-title":"Lancet Neurol."},{"key":"1670_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2024.109664","volume":"152","author":"JA Thomas","year":"2024","unstructured":"Thomas, J. A., Ditchman, N. M., Guidotti Breting, L. & Narayanan, J. Quality of life in people with epilepsy: The associations of anti-seizure medications and biopsychosocial variables. Epilepsy Behav. 152, 109664 (2024).","journal-title":"Epilepsy Behav."},{"key":"1670_CR7","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s40263-024-01105-z","volume":"38","author":"K Wong","year":"2024","unstructured":"Wong, K. et al. Caregiver perspective of benefits and side effects of anti-seizure medications in CDKL5 deficiency disorder from an international database. CNS Drugs 38, 719\u2013732 (2024).","journal-title":"CNS Drugs"},{"key":"1670_CR8","doi-asserted-by":"publisher","first-page":"e0196587","DOI":"10.1371\/journal.pone.0196587","volume":"13","author":"K Okuda","year":"2018","unstructured":"Okuda, K. et al. Comprehensive behavioral analysis of the Cdkl5 knockout mice revealed significant enhancement in anxiety- and fear-related behaviors and impairment in both acquisition and long-term retention of spatial reference memory. PLoS ONE 13, e0196587 (2018).","journal-title":"PLoS ONE"},{"key":"1670_CR9","doi-asserted-by":"crossref","unstructured":"Terzic, B. et al. Temporal manipulation of Cdkl5 reveals essential postdevelopmental functions and reversible CDKL5 deficiency disorder-related deficits. J. Clin. Invest. 131, e143655 (2021).","DOI":"10.1172\/JCI143655"},{"key":"1670_CR10","doi-asserted-by":"publisher","first-page":"21516","DOI":"10.1073\/pnas.1216988110","volume":"109","author":"IT Wang","year":"2012","unstructured":"Wang, I. T. et al. Loss of CDKL5 disrupts kinome profile and event-related potentials leading to autistic-like phenotypes in mice. Proc. Natl Acad. Sci. USA 109, 21516\u201321521 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1670_CR11","doi-asserted-by":"publisher","first-page":"e91613","DOI":"10.1371\/journal.pone.0091613","volume":"9","author":"E Amendola","year":"2014","unstructured":"Amendola, E. et al. Mapping pathological phenotypes in a mouse model of CDKL5 disorder. PLoS ONE 9, e91613 (2014).","journal-title":"PLoS ONE"},{"key":"1670_CR12","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3389\/fncel.2016.00261","volume":"10","author":"R Pizzo","year":"2016","unstructured":"Pizzo, R. et al. Lack of Cdkl5 disrupts the organization of excitatory and inhibitory synapses and parvalbumin interneurons in the primary visual cortex. Front. Cell Neurosci. 10, 261 (2016).","journal-title":"Front. Cell Neurosci."},{"key":"1670_CR13","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.1093\/hmg\/ddad149","volume":"32","author":"W Liao","year":"2023","unstructured":"Liao, W. & Lee, K. Z. CDKL5-mediated developmental tuning of neuronal excitability and concomitant regulation of transcriptome. Hum. Mol. Genet. 32, 3276\u20133298 (2023).","journal-title":"Hum. Mol. Genet."},{"key":"1670_CR14","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.tins.2021.01.004","volume":"44","author":"MA Virtanen","year":"2021","unstructured":"Virtanen, M. A., Uvarov, P., Mavrovic, M., Poncer, J. C. & Kaila, K. The multifaceted roles of KCC2 in cortical development. Trends Neurosci. 44, 378\u2013392 (2021).","journal-title":"Trends Neurosci."},{"key":"1670_CR15","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.tins.2017.06.008","volume":"40","author":"YE Moore","year":"2017","unstructured":"Moore, Y. E., Kelley, M. R., Brandon, N. J., Deeb, T. Z. & Moss, S. J. Seizing control of KCC2: a new therapeutic target for epilepsy. Trends Neurosci. 40, 555\u2013571 (2017).","journal-title":"Trends Neurosci."},{"key":"1670_CR16","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3389\/fnmol.2019.00173","volume":"12","author":"YE Moore","year":"2019","unstructured":"Moore, Y. E. et al. Developmental regulation of KCC2 phosphorylation has long-term impacts on cognitive function. Front. Mol. Neurosci. 12, 173 (2019).","journal-title":"Front. Mol. Neurosci."},{"key":"1670_CR17","doi-asserted-by":"publisher","first-page":"29777","DOI":"10.1074\/jbc.M705053200","volume":"282","author":"HH Lee","year":"2007","unstructured":"Lee, H. H. et al. Direct protein kinase C-dependent phosphorylation regulates the cell surface stability and activity of the potassium chloride cotransporter KCC2. J. Biol. Chem. 282, 29777\u201329784 (2007).","journal-title":"J. Biol. Chem."},{"key":"1670_CR18","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.neuropharm.2016.04.029","volume":"108","author":"MR Kelley","year":"2016","unstructured":"Kelley, M. R. et al. Compromising KCC2 transporter activity enhances the development of continuous seizure activity. Neuropharmacology 108, 103\u2013110 (2016).","journal-title":"Neuropharmacology"},{"key":"1670_CR19","doi-asserted-by":"publisher","first-page":"8291","DOI":"10.1523\/JNEUROSCI.5205-14.2015","volume":"35","author":"S Sivakumaran","year":"2015","unstructured":"Sivakumaran, S. et al. Selective inhibition of KCC2 leads to hyperexcitability and epileptiform discharges in hippocampal slices and in vivo. J. Neurosci. 35, 8291\u20138296 (2015).","journal-title":"J. Neurosci."},{"key":"1670_CR20","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/epi.12037","volume":"53","author":"TZ Deeb","year":"2012","unstructured":"Deeb, T. Z., Maguire, J. & Moss, S. J. Possible alterations in GABAA receptor signaling that underlie benzodiazepine-resistant seizures. Epilepsia 53, 79\u201388 (2012).","journal-title":"Epilepsia"},{"key":"1670_CR21","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.expneurol.2007.01.001","volume":"204","author":"LS Deshpande","year":"2007","unstructured":"Deshpande, L. S. et al. Development of pharmacoresistance to benzodiazepines but not cannabinoids in the hippocampal neuronal culture model of status epilepticus. Exp. Neurol. 204, 705\u2013713 (2007).","journal-title":"Exp. Neurol."},{"key":"1670_CR22","doi-asserted-by":"publisher","first-page":"e68851","DOI":"10.1371\/journal.pone.0068851","volume":"8","author":"ST Duarte","year":"2013","unstructured":"Duarte, S. T. et al. Abnormal expression of cerebrospinal fluid cation chloride cotransporters in patients with Rett syndrome. PLoS ONE 8, e68851 (2013).","journal-title":"PLoS ONE"},{"key":"1670_CR23","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1523\/JNEUROSCI.4447-13.2014","volume":"34","author":"Q He","year":"2014","unstructured":"He, Q., Nomura, T., Xu, J. & Contractor, A. The developmental switch in GABA polarity is delayed in fragile X mice. J. Neurosci. 34, 446\u2013450 (2014).","journal-title":"J. Neurosci."},{"key":"1670_CR24","doi-asserted-by":"crossref","unstructured":"Tang, X. et al. Pharmacological enhancement of KCC2 gene expression exerts therapeutic effects on human Rett syndrome neurons and Mecp2 mutant mice. Sci. Transl. Med. 11, eaau0164 (2019).","DOI":"10.1126\/scitranslmed.aau0164"},{"key":"1670_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.100957","volume":"4","author":"R Jarvis","year":"2023","unstructured":"Jarvis, R. et al. Direct activation of KCC2 arrests benzodiazepine refractory status epilepticus and limits the subsequent neuronal injury in mice. Cell Rep. Med. 4, 100957 (2023).","journal-title":"Cell Rep. Med."},{"key":"1670_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2022.1017404","volume":"15","author":"C Choi","year":"2022","unstructured":"Choi, C. et al. Analyzing the mechanisms that facilitate the subtype-specific assembly of \u03b3-aminobutyric acid type A receptors. Front. Mol. Neurosci. 15, 1017404 (2022).","journal-title":"Front. Mol. Neurosci."},{"key":"1670_CR27","doi-asserted-by":"crossref","unstructured":"Smalley, J. L. et al. Isolation and Characterization of multi-protein complexes enriched in the K\u2013Cl co-transporter 2 from brain plasma membranes. Front. Mol. Neurosci. 13, 563091 (2020).","DOI":"10.3389\/fnmol.2020.563091"},{"key":"1670_CR28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s42003-022-04381-x","volume":"6","author":"JL Smalley","year":"2023","unstructured":"Smalley, J. L. et al. Spectrin-\u03b2 2 facilitates the selective accumulation of GABAA receptors at somatodendritic synapses. Commun. Biol. 6, 11 (2023).","journal-title":"Commun. Biol."},{"key":"1670_CR29","doi-asserted-by":"publisher","first-page":"e18218","DOI":"10.1371\/journal.pone.0018218","volume":"6","author":"R Antrobus","year":"2011","unstructured":"Antrobus, R. & Borner, G. H. H. Improved elution conditions for native co-immunoprecipitation. PLoS ONE 6, e18218 (2011).","journal-title":"PLoS ONE"},{"key":"1670_CR30","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.nbd.2016.11.002","volume":"98","author":"A Pirone","year":"2017","unstructured":"Pirone, A. et al. APC conditional knock-out mouse is a model of infantile spasms with elevated neuronal \u03b2-catenin levels, neonatal spasms, and chronic seizures. Neurobiol. Dis. 98, 149\u2013157 (2017).","journal-title":"Neurobiol. Dis."},{"key":"1670_CR31","doi-asserted-by":"publisher","first-page":"8752","DOI":"10.1523\/JNEUROSCI.0915-09.2009","volume":"29","author":"MG Price","year":"2009","unstructured":"Price, M. G. et al. A triplet repeat expansion genetic mouse model of infantile spasms syndrome, Arx(GCG)10+7, with interneuronopathy, spasms in infancy, persistent seizures, and adult cognitive and behavioral impairment. J. Neurosci. 29, 8752\u20138763 (2009).","journal-title":"J. Neurosci."},{"key":"1670_CR32","doi-asserted-by":"crossref","unstructured":"Colmers, P. L. W. et al. Sustained inhibition of GABA-AT by OV329 enhances neuronal inhibition and prevents development of benzodiazepine refractory seizures. eNeuro 11, ENEURO.0137-24.2024 (2024).","DOI":"10.1523\/ENEURO.0137-24.2024"},{"key":"1670_CR33","doi-asserted-by":"publisher","DOI":"10.21769\/BioProtoc.3533","volume":"10","author":"MN Arshad","year":"2020","unstructured":"Arshad, M. N. & Naegele, J. R. Induction of temporal lobe epilepsy in mice with pilocarpine. Bio Protoc. 10, e3533 (2020).","journal-title":"Bio Protoc."},{"key":"1670_CR34","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.1073\/pnas.1415126112","volume":"112","author":"L Silayeva","year":"2015","unstructured":"Silayeva, L. et al. KCC2 activity is critical in limiting the onset and severity of status epilepticus. Proc. Natl Acad. Sci. USA 112, 3523\u20133528 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1670_CR35","doi-asserted-by":"publisher","first-page":"10166","DOI":"10.1073\/pnas.1810134115","volume":"115","author":"YE Moore","year":"2018","unstructured":"Moore, Y. E., Deeb, T. Z., Chadchankar, H., Brandon, N. J. & Moss, S. J. Potentiating KCC2 activity is sufficient to limit the onset and severity of seizures. Proc. Natl Acad. Sci. USA 115, 10166\u201310171 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1670_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.109512","volume":"27","author":"N Cho","year":"2024","unstructured":"Cho, N. et al. The brain-specific kinase LMTK3 regulates neuronal excitability by decreasing KCC2-dependent neuronal Cl\u2212 extrusion. iScience 27, 109512 (2024).","journal-title":"iScience"},{"key":"1670_CR37","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.neuint.2016.05.006","volume":"97","author":"H Baek","year":"2016","unstructured":"Baek, H. et al. Altered expression of KCC2 in GABAergic interneuron contributes prenatal stress-induced epileptic spasms in infant rat. Neurochem. Int. 97, 57\u201364 (2016).","journal-title":"Neurochem. Int."},{"key":"1670_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/srep30072","volume":"6","author":"H Saitsu","year":"2016","unstructured":"Saitsu, H. et al. Impaired neuronal KCC2 function by biallelic SLC12A5 mutations in migrating focal seizures and severe developmental delay. Sci. Rep. 6, 30072 (2016).","journal-title":"Sci. Rep."},{"key":"1670_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9038","volume":"6","author":"T St\u00f6dberg","year":"2015","unstructured":"St\u00f6dberg, T. et al. Mutations in SLC12A5 in epilepsy of infancy with migrating focal seizures. Nat. Commun. 6, 8038 (2015).","journal-title":"Nat. Commun."},{"key":"1670_CR40","doi-asserted-by":"crossref","unstructured":"Furukawa, M. et al. Neonatal maternal separation delays the GABA excitatory-to-inhibitory functional switch by inhibiting KCC2 expression. Biochem. Biophys. Res. Commun. 3,1243\u20131249 (2017).","DOI":"10.1016\/j.bbrc.2017.09.143"},{"key":"1670_CR41","doi-asserted-by":"crossref","unstructured":"Reh, R. K. et al. Critical period regulation across multiple timescales. Proc. Natl. Acad. Sci. USA 117, 23242\u201323251 (2020).","DOI":"10.1073\/pnas.1820836117"},{"key":"1670_CR42","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcac197","volume":"4","author":"JN Saby","year":"2022","unstructured":"Saby, J. N. et al. Electrophysiological biomarkers of brain function in CDKL5 deficiency disorder. Brain Commun. 4, fcac197 (2022).","journal-title":"Brain Commun."},{"key":"1670_CR43","doi-asserted-by":"crossref","unstructured":"Pisella, L. I. et al. Impaired regulation of KCC2 phosphorylation leads to neuronal network dysfunction and neurodevelopmental pathology. Sci. Signal. 12, eaay0300 (2019)","DOI":"10.1126\/scisignal.aay0300"},{"key":"1670_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41401-023-01149-9","volume":"45","author":"E McMoneagle","year":"2024","unstructured":"McMoneagle, E. et al. Neuronal K+\u2013Cl\u2212 cotransporter KCC2 as a promising drug target for epilepsy treatment. Acta Pharmacol. Sin. 45, 1\u201322 (2024).","journal-title":"Acta Pharmacol. Sin."},{"key":"1670_CR45","doi-asserted-by":"publisher","DOI":"10.1177\/17448069231185439","volume":"19","author":"Z Hu","year":"2023","unstructured":"Hu, Z. et al. BDNF\u2013TrkB signaling pathway-mediated microglial activation induces neuronal KCC2 downregulation contributing to dynamic allodynia following spared nerve injury. Mol. Pain 19, 17448069231185439 (2023).","journal-title":"Mol. Pain"},{"key":"1670_CR46","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1083\/jcb.200209011","volume":"159","author":"C Rivera","year":"2002","unstructured":"Rivera, C. et al. BDNF-induced TrkB activation down-regulates the K+\u2013Cl\u2212 cotransporter KCC2 and impairs neuronal Cl\u2212 extrusion. J. Cell Biol. 159, 747\u2013752 (2002).","journal-title":"J. Cell Biol."},{"key":"1670_CR47","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.neuroscience.2012.05.003","volume":"219","author":"X Huang","year":"2012","unstructured":"Huang, X., McMahon, J., Yang, J., Shin, D. & Huang, Y. Rapamycin down-regulates KCC2 expression and increases seizure susceptibility to convulsants in immature rats. Neuroscience 219, 33\u201347 (2012).","journal-title":"Neuroscience"},{"key":"1670_CR48","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1111\/epi.16805","volume":"62","author":"HT Wang","year":"2021","unstructured":"Wang, H. T. et al. CDKL5 deficiency in forebrain glutamatergic neurons results in recurrent spontaneous seizures. Epilepsia 62, 517\u2013528 (2021).","journal-title":"Epilepsia"},{"key":"1670_CR49","doi-asserted-by":"crossref","unstructured":"Glass, M. R. et al. Excitatory cortical neurons from CDKL5 deficiency disorder patient-derived organoids show early hyperexcitability not identified in neurogenin2 induced neurons. Neurobiol. Dis. 215, 107093 (2025).","DOI":"10.1016\/j.nbd.2025.107093"},{"key":"1670_CR50","doi-asserted-by":"publisher","first-page":"588","DOI":"10.3389\/fneur.2017.00588","volume":"8","author":"D Bertoglio","year":"2017","unstructured":"Bertoglio, D. et al. Kainic acid-induced post-status epilepticus models of temporal lobe epilepsy with diverging seizure phenotype and neuropathology. Front. Neurol. 8, 588 (2017).","journal-title":"Front. Neurol."},{"key":"1670_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2021.106816","volume":"178","author":"ND Drysdale","year":"2021","unstructured":"Drysdale, N. D., Matthews, E., Schuetz, E., Pan, E. & McNamara, J. O. Intravenous kainic acid induces status epilepticus and late onset seizures in mice. Epilepsy Res. 178, 106816 (2021).","journal-title":"Epilepsy Res."},{"key":"1670_CR52","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1177\/0192623308326093","volume":"36","author":"AK Sharma","year":"2008","unstructured":"Sharma, A. K., Jordan, W. H., Reams, R. Y., Hall, D. G. & Snyder, P. W. Temporal profile of clinical signs and histopathologic changes in an F-344 rat model of kainic acid-induced mesial temporal lobe epilepsy. Toxicol. Pathol. 36, 932\u2013943 (2008).","journal-title":"Toxicol. Pathol."},{"key":"1670_CR53","doi-asserted-by":"publisher","first-page":"3922","DOI":"10.1093\/hmg\/ddx279","volume":"26","author":"C-L Jhang","year":"2017","unstructured":"Jhang, C.-L., Huang, T.-N., Hsueh, Y.-P. & Liao, W. Mice lacking cyclin-dependent kinase-like 5 manifest autistic and ADHD-like behaviors. Hum. Mol. Genet. 26, 3922\u20133934 (2017).","journal-title":"Hum. Mol. Genet."},{"key":"1670_CR54","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1093\/hmg\/ddaa122","volume":"29","author":"CL Jhang","year":"2020","unstructured":"Jhang, C. L., Lee, H. Y., Chen, J. C. & Liao, W. Dopaminergic loss of cyclin-dependent kinase-like 5 recapitulates methylphenidate-remediable hyperlocomotion in mouse model of CDKL5 deficiency disorder. Hum. Mol. Genet. 29, 2408\u20132419 (2020).","journal-title":"Hum. Mol. Genet."},{"key":"1670_CR55","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.neuron.2015.06.017","volume":"87","author":"A Contractor","year":"2015","unstructured":"Contractor, A., Klyachko, V. A. & Portera-Cailliau, C. Altered neuronal and circuit excitability in Fragile X syndrome. Neuron 87, 699\u2013715 (2015).","journal-title":"Neuron"},{"key":"1670_CR56","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1073\/pnas.1524013113","volume":"113","author":"X Tang","year":"2016","unstructured":"Tang, X. et al. KCC2 rescues functional deficits in human neurons derived from patients with Rett syndrome. Proc. Natl Acad. Sci. USA 113, 751\u2013756 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1670_CR57","doi-asserted-by":"publisher","first-page":"e1429242025","DOI":"10.1523\/JNEUROSCI.1429-24.2025","volume":"45","author":"NC Cottam","year":"2025","unstructured":"Cottam, N. C. et al. From circuits to lifespan: translating mouse and human timelines with neuroimaging-based tractography. J. Neurosci. 45, e1429242025 (2025).","journal-title":"J. Neurosci."},{"key":"1670_CR58","doi-asserted-by":"crossref","unstructured":"Schneider, A. C. et al. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 9, 671\u2013675 (2012).","DOI":"10.1038\/nmeth.2089"}],"container-title":["Experimental &amp; Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01670-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01670-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01670-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T13:06:48Z","timestamp":1773839208000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01670-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":58,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["1670"],"URL":"https:\/\/doi.org\/10.1038\/s12276-026-01670-x","relation":{},"ISSN":["2092-6413"],"issn-type":[{"value":"2092-6413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]},"assertion":[{"value":"8 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.J.M. serves as a consultant for AstraZeneca, Ovid Therapeutics and Sage Therapeutics, relationships that are regulated by Tufts University. S.F.J.N. and S.J.M. hold equity in Ovid Therapeutics. T.N. and Z.Z. are employees of Ovid Therapeutics and hold equity. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}